(Melrilimab)Biosimilar-Reference-Antibody-GS40429 新品

货号：GS40429

Melrilimab is a human IgG2-kappa (IgG2κ) monoclonal antibody that specifically targets the interleukin-33 receptor (IL‑33R), also known as IL1RL1, ST2, DER4, or FIT‑1. The IgG2 isotype is selected to minimize effector functions such as antibody-dependent cellular cytotoxicity (ADCC). By binding to IL‑33R with high affinity, it blocks the interaction between the receptor and its cytokine ligand IL‑33, thereby inhibiting downstream signaling through the MYD88/NF‑κB pathway. This blockade aims to suppress the type 2 inflammatory responses driven by IL‑33. It is being developed for the treatment of allergic and inflammatory diseases in which the IL‑33/ST2 axis plays a central role, such as asthma, atopic dermatitis, and chronic obstructive pulmonary disease (COPD).